↓ Skip to main content

Dove Medical Press

Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis

Overview of attention for article published in Open Access Rheumatology : Research and Reviews , February 2014
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#50 of 188)
  • High Attention Score compared to outputs of the same age (81st percentile)

Mentioned by

policy
1 policy source
twitter
1 X user
patent
6 patents

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
28 Mendeley
Title
Profile of ustekinumab and its potential in the treatment of active psoriatic arthritis
Published in
Open Access Rheumatology : Research and Reviews , February 2014
DOI 10.2147/oarrr.s56048
Pubmed ID
Authors

Monica Montepaone, Ennio Lubrano, Alessia Carboni, Antonio Spadaro

Abstract

Psoriatic arthritis (PsA) is a chronic inflammatory arthritis and considered to be a less severe condition than rheumatoid arthritis. PsA patients have been treated for a long time with a number of different agents, from non-steroidal anti-inflammatory drugs to one or more disease-modifying antirheumatic drugs. In the last decade, recognition of the central role of tumor necrosis factor-alpha (TNFα) in the immunopathogenesis of many rheumatic diseases, including PsA, has led to the development of TNFα blockers. In PsA, these agents are uniquely efficacious in the treatment of different patterns of the disease, as well as slowing progression of erosive damage in the peripheral joints. However, a significant number of patients withdraw from therapy because of failure or poor tolerability. Among the novel therapeutic targets, interleukin (IL)-23/IL-12 has been investigated for the treatment of chronic inflammatory disease. In particular, ustekinumab is a human monoclonal antibody that prevents human IL-12 and IL-23 from binding to the IL-12Rβ1 receptor chain of IL-12 (IL-12Rβ1/β2) and IL-23 (IL-12Rβ1/23R) receptor complexes on the surface of natural killer cells and T-cells. Ustekinumab has been approved only for treatment of chronic plaque psoriasis, but also represents an interesting agent for treatment of PsA.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 28 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 28 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 9 32%
Student > Ph. D. Student 6 21%
Student > Bachelor 3 11%
Student > Postgraduate 2 7%
Student > Master 1 4%
Other 1 4%
Unknown 6 21%
Readers by discipline Count As %
Medicine and Dentistry 15 54%
Pharmacology, Toxicology and Pharmaceutical Science 2 7%
Biochemistry, Genetics and Molecular Biology 1 4%
Social Sciences 1 4%
Immunology and Microbiology 1 4%
Other 2 7%
Unknown 6 21%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 August 2023.
All research outputs
#5,340,716
of 25,584,565 outputs
Outputs from Open Access Rheumatology : Research and Reviews
#50
of 188 outputs
Outputs of similar age
#58,985
of 323,682 outputs
Outputs of similar age from Open Access Rheumatology : Research and Reviews
#1
of 3 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 188 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one has gotten more attention than average, scoring higher than 73% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 323,682 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 81% of its contemporaries.
We're also able to compare this research output to 3 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them